Brit J Anaesth:急性呼吸窘迫综合征幸存者的生理和心理障碍情况分析

2022-08-28 MedSci原创 MedSci原创

急性呼吸窘迫综合征幸存者的健康相关生活质量降低,身心健康受损,症状可能在ICU出院后5年内都无法完全恢复。

急性呼吸窘迫综合征的幸存者有长期合并症的风险。近日,麻醉学领域权威杂志British Journal of Anaesthesia上发表了一篇研究文章,该系统回顾和荟萃分析旨在评估急性呼吸窘迫综合征幸存者丛重症监护室出院后随访3个月至5年内的健康相关生活质量、身体和心理障碍情况。

研究人员全面地检索了PubMed、AMED、BNI、CINAHL数据库,检索时间从2000年1月至今(PROSPERO:CRD42021296506)。该研究的主要观察指标为健康相关生活质量,次要结局包括身体、肺和认知功能、心理健康和重返工作岗位。二次分析比较了经典急性呼吸窘迫综合征与SARS-CoV-2急性呼吸窘迫综合征患者的特点。

48篇文献符合纳入标准,共包含11693例患者;其中典型急性呼吸窘迫综合征占85%(n=9992),SARS-CoV-2急性呼吸窘迫综合征占14%(n=1632)。SF-36体质成分总结评分平均值在3个月时为46(95%CI为41,50),6个月时为39(95%CI为36,41),12个月时为40(95%CI为38,43)。SF-36心理成分综合平均分3个月时为53(95%CI为48,57),6个月时为45(95%CI为40,50),12个月时为44(95%CI为42,47)。SF-36低于正常人群值达5年之久。

3个月、6个月和12个月时6分钟步行预测距离分别为57%(95%CI为45,69)、63%(95%CI为56,69)和66%(95%CI为62,70)。典型急性呼吸窘迫综合征与SARS-CoV-2急性呼吸窘迫综合征患者在生命质量和身体功能方面无显著差异;典型急性呼吸窘迫综合征患者焦虑、抑郁发生率较高(p<0.001)。

由此可见,急性呼吸窘迫综合征幸存者的健康相关生活质量降低,身心健康受损,症状可能在ICU出院后5年内都无法完全恢复。

原始出处:

Brigitta Fazzini.et al.Physical and psychological impairment in survivors with acute respiratory distress syndrome: a systematic review and meta-analysis.British Journal of Anaesthesia.2022.https://www.bjanaesthesia.org/article/S0007-0912(22)00455-X/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633657, encodeId=aa9d163365ec5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Mar 17 05:10:17 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051839, encodeId=1648205183908, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue May 02 12:10:17 CST 2023, time=2023-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432384, encodeId=9d391432384d4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582299, encodeId=8d6d1582299e3, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2023-03-17 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633657, encodeId=aa9d163365ec5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Mar 17 05:10:17 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051839, encodeId=1648205183908, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue May 02 12:10:17 CST 2023, time=2023-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432384, encodeId=9d391432384d4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582299, encodeId=8d6d1582299e3, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2023-05-02 xiangyuzhou971
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633657, encodeId=aa9d163365ec5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Mar 17 05:10:17 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051839, encodeId=1648205183908, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue May 02 12:10:17 CST 2023, time=2023-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432384, encodeId=9d391432384d4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582299, encodeId=8d6d1582299e3, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633657, encodeId=aa9d163365ec5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Mar 17 05:10:17 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051839, encodeId=1648205183908, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue May 02 12:10:17 CST 2023, time=2023-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432384, encodeId=9d391432384d4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582299, encodeId=8d6d1582299e3, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Aug 30 07:10:17 CST 2022, time=2022-08-30, status=1, ipAttribution=)]

相关资讯

Crit Care:体外膜肺氧合治疗COVID-19和H1N1流感相关急性呼吸窘迫综合征效果比较

在接受体外膜肺氧合的ARDS患者中,研究人员观察到未经调整的60天死亡率在COVID-19患者中高于H1N1肺炎患者。多变量调整后,死亡率的差异不显著。

NEJM:脂肪栓塞综合征的少见病因

26岁,女性。 腹壁成形术和抽脂术3天后出现呼吸衰竭和精神状态改变。

表面活性剂治疗晚期早产儿和足月新生儿呼吸窘迫综合征

在过去的几十年里,呼吸窘迫综合征 (RDS) 的管理有了很大的发展,外源性表面活性剂替代品是其特殊的基石之一。

Crit Care:基于肺形态的急性呼吸窘迫综合征患者一年结局

肺形态反映了ARDS的急性期及其短期影响,但不反映长期结局,并且这只受合并症的影响。

Chest:阿司匹林治疗急性呼吸窘迫综合征的疗效分析

阿司匹林的耐受性良好,但并没有改善受试者OI或其他生理结局,在当前实验设计中开展更大型的试验是不可行的。

Crit Care:急性呼吸窘迫综合征(ARDS)的COVID-19患者早期短疗程神经肌肉阻断剂的治疗效果

对于中重度急性呼吸窘迫综合征(ARDS)的COVID-19患者,早期开始NMBA短程治疗并没有显著改善患者90天死亡率和VFD。在缺乏来自临床试验的明确数据的情况下,这类患者应谨慎使用NMBA。